Exhibit 99.1

LOGO

NEWS RELEASE

Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2009

Acquisition of P&G’s Global Branded Pharmaceuticals Business and increased revenues from legacy promoted products drive revenue growth.

ARDEE, IRELAND, MARCH 1, 2010 – Warner Chilcott plc (NASDAQ: WCRX) today announced its results for the quarter and year ended December 31, 2009. Revenue in the quarter was $686.2 million, an increase of $443.7 million, or 183.0%, over the prior year quarter revenue of $242.5 million. The primary drivers of the increase in revenue were the products acquired from The Procter & Gamble Company (“P&G”) on October 30, 2009, primarily ACTONEL, ASACOL and ENABLEX, which together contributed $351.8 million of revenue growth in the quarter ended December 31, 2009. For the quarter ended December 31, 2009, revenues contributed by all of the new products acquired from P&G totaled $374.0 million. We also delivered strong revenue growth compared to the prior year quarter from our promoted legacy products LOESTRIN 24 FE, DORYX and ESTRACE CREAM. Together these products contributed $52.9 million of revenue growth compared to the prior year quarter. The growth delivered by these products was offset in part by net sales declines of other products.

The acquisition of the global branded pharmaceuticals business of P&G on October 30, 2009 (the “PGP Acquisition”) significantly impacted the Company’s financial position and results of operations in the quarter ended December 31, 2009. The Company reported a GAAP net (loss) of $(9.5) million, or $(0.04) per diluted share, in the quarter ended December 31, 2009, compared with a GAAP net (loss) of $(115.7) million, or $(0.46) per diluted share, in the prior year quarter. Included in the Company’s fourth quarter results was a $65.1 million expense, net of tax, attributable to a purchase accounting adjustment that increased the opening value of the inventories acquired in the PGP Acquisition that was recorded in cost of sales as that inventory was sold. Also included in the results for the quarter ended December 31, 2009 was a $33.5 million gain, net of tax, resulting from the Company’s sale of certain inventories to LEO Pharma A/S (“LEO”) in connection with a transaction completed during the third quarter of 2009 and more fully described below. The quarter ended December 31, 2008 included a $160.1 million, net of tax, non-cash impairment charge related to our OVCON/FEMCON FE intangible asset. Cash net income (“CNI”) as reported in the quarter ended December 31, 2009 was $133.4 million compared to $100.5 million in the prior year quarter. Excluding the purchase accounting expense included in cost of sales and the gain relating to the sale of certain inventories in connection with the below described transaction with LEO, adjusted CNI was $165.0 million, or $0.65 per diluted share, in the quarter ended December 31, 2009.

References in this release to “cash net income” or “CNI” mean our net income adjusted for the after-tax effects of two non-cash items: amortization (including impairments, if any) of intangible assets and amortization (including write-offs, if any) of deferred loan costs related to our debt. Reconciliations from our reported results in accordance with US GAAP to CNI, adjusted CNI and adjusted earnings before interest, taxes, depreciation and amortization (“EBITDA”) for all periods are presented in the tables at the end of this press release.

 

1


The following information was filed by Warner Chilcott Plc (WCRX) on Monday, March 1, 2010 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Warner Chilcott Plc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Warner Chilcott Plc.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account